Obesity is one of the most prevalent diseases globally, leading to insulin resistance and atherosclerosis, which are driven by obesity-associated chronic inflammation. A hallmark of obesity-associated inflammation is a switch from alternative-activated (M2) to classically-activated pro-inflammatory (M1) macrophage in adipose tissue with enhanced local and systemic inflammation and impaired immune function. Of interest, M1 macrophages require glucose as an energy source, while alternative activated (M2) macrophages switch to fatty acid oxidation for energy needs. Despite the critical role of glucose metabolism during macrophage activation, molecular mechanisms linking altered glucose metabolism to macrophage polarization are not well understood. Solute carrier (SLC) 37A2 has been reported anchored in the endoplasmic reticulum (ER) membrane and is a phosphate-linked glucose-6-phosphate (G6P) transporter. SLC37A2 is highly expressed in macrophages and neutrophils relative to other SLC37 family members. Our preliminary data suggest that macrophage SLC37A2 is acutely downregulated during classical activation and upregulated during alternative activation. Suppression of SLC37A2 is sufficient to promote M1 and attenuate M2 polarization of mouse macrophages. Conversely, constitutive overexpression of SLC37A2 blunts M1 polarization in response to Toll like receptor (TLR) agonists. This proposal aims to explore a novel SLC37A2-mediated metabolic reprogramming pathway, which plays a critical role in regulating macrophage glucose flux, utilization and fatty acid oxidation. We will test a novel hypothesis that SLC37A2 promotes macrophage M1 to M2 phenotypic switch by regulating intracellular glucose utilization and homeostasis, protecting against insulin resistance and atherosclerosis. The proposed studies will demonstrate whether SLC37A2 regulates macrophage glucose metabolism and reprograms macrophage M1/M2 polarization. This project, led by a New Investigator with an expert multidisciplinary team, will provide novel information regarding the role of glucose metabolism in macrophage phenotypic switching, and has the potential to lead to novel therapeutic strategies for chronic inflammatory diseases driven by M1-skewed proinflammatory macrophages.

Public Health Relevance

Obesity is one of the most prevalent diseases globally and cardiovascular disease is the leading cause of death in the US. This project is designed to test a novel hypothesis that a sugar transporter SLC37A2, exerts protection against obesity associated chronic inflammatory diseases via attenuation of macrophage inflammation. This project has the potential to lead to novel therapeutic strategies for chronic inflammatory diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL132035-02
Application #
9234061
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Chen, Jue
Project Start
2016-03-01
Project End
2021-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
2
Fiscal Year
2017
Total Cost
$370,377
Indirect Cost
$131,424
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157